$SHOT
Safety Shot, Inc. Stock $shot

$shot Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031766 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$905.6K	$1.570M	$687.9K
YoY Change	-41.36%	128.21%	282.18%
Cost Of Revenue	$915.0K	$1.156M	$685.8K
YoY Change	-24.85%	68.51%	585.77%
Gross Profit	-$9.400K	$413.3K	$2.160K
YoY Change	-102.88%	19034.63%	-97.3%
Gross Profit Margin	-1.04%	26.33%	0.31%
Selling, General & Admin	$6.210M	$2.169M	$2.859M
YoY Change	-7.19%	-24.13%	393.0%
% of Gross Profit		524.9%	132379.17%
Research & Development	$672.6K	$3.880K	$722.0K
YoY Change	316.05%	-99.46%	2306.67%
% of Gross Profit		0.94%	33425.93%
Depreciation & Amortization	$448.2K	$25.37K	-$5.930K
YoY Change	199.93%	-527.82%	-119.77%
% of Gross Profit		6.14%	-274.54%
Operating Expenses	$6.906M	$2.197M	$3.609M
YoY Change	-59.31%	-39.14%	455.26%
Operating Profit	-$6.915M	-$1.783M	-$3.607M
YoY Change	-58.45%	-50.56%	532.82%
Interest Expense	-$161.7K	-$549.2K	-$1.196M
YoY Change	331.0%	-54.09%	2890.65%
% of Operating Profit
Other Income/Expense, Net	-$3.270K	-$549.2K	-$5.110K
YoY Change	-109.18%	10648.18%
Pretax Income	-$8.530M	-$2.332M	-$4.808M
YoY Change	-49.66%	-51.49%	688.27%
Income Tax
% Of Pretax Income
Net Earnings	-$8.530M	-$2.332M	-$4.808M
YoY Change	-49.66%	-51.49%	688.27%
Net Earnings / Revenue	-941.91%	-148.57%	-698.97%
Basic Earnings Per Share		-$0.10	-$0.24
Diluted Earnings Per Share	-$0.39	-$0.10	-$242.6K
COMMON SHARES
Basic Shares Outstanding	21.89M shares	21.51M shares	19.82M shares
Diluted Shares Outstanding		21.53M shares	19.82M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.848M	$6.474M	$27.15M
YoY Change	-66.93%	-76.15%	20782.01%
Cash & Equivalents	$1.931M	$3.565M	$26.85M
Short-Term Investments	$2.917M	$2.908M	$293.3K
Other Short-Term Assets	$814.1K	$880.2K	$56.37K
YoY Change	31.88%	1461.38%	-29.54%
Inventory	$441.4K	$397.3K	$637.0K
Prepaid Expenses	$814.1K	$880.2K
Receivables	$647.5K	$649.7K	$571.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.751M	$8.401M	$28.41M
YoY Change	-58.53%	-70.43%	5161.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$61.83K	$87.20K	$941.1K
YoY Change	-43.31%	-90.73%	2252.75%
Goodwill	$941.9K	$941.9K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$1.288M
YoY Change
Total Long-Term Assets	$1.939M	$3.685M	$3.037M
YoY Change	-25.06%	21.31%	146.94%
TOTAL ASSETS
Total Short-Term Assets	$6.751M	$8.401M	$28.41M
Total Long-Term Assets	$1.939M	$3.685M	$3.037M
Total Assets	$8.691M	$12.09M	$31.45M
YoY Change	-53.94%	-61.57%	1676.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.927M	$572.3K	$801.8K
YoY Change	55.05%	-28.62%	7917.5%
Accrued Expenses	$366.6K	$296.0K	$215.7K
YoY Change	128.41%	37.21%	208.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$2.048M	$1.940M	$84.35K
YoY Change	4206.06%	2200.39%	-94.22%
Total Short-Term Liabilities	$4.506M	$2.964M	$1.102M
YoY Change	187.14%	168.99%	-56.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$519.7K	$564.9K	$720.0K
YoY Change	-25.33%	-21.54%	2299.97%
Total Long-Term Liabilities	$519.7K	$564.9K	$720.0K
YoY Change	-25.33%	-21.54%	2299.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.506M	$2.964M	$1.102M
Total Long-Term Liabilities	$519.7K	$564.9K	$720.0K
Total Liabilities	$5.025M	$3.529M	$1.822M
YoY Change	121.86%	93.69%	-28.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$50.60M	-$42.07M
YoY Change	43.03%
Common Stock	$22.34K	$21.66K
YoY Change	-7.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$300.2K
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.666M	$8.557M	$29.63M
YoY Change
Total Liabilities & Shareholders Equity	$8.691M	$12.09M	$31.45M
YoY Change	-53.94%	-61.57%	1676.79%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$8.530M	-$2.332M	-$4.808M
YoY Change	-49.66%	-51.49%	688.27%
Depreciation, Depletion And Amortization	$448.2K	$25.37K	-$5.930K
YoY Change	199.93%	-527.82%	-119.77%
Cash From Operating Activities	-$1.646M	-$1.041M	-$1.780M
YoY Change	-35.47%	-41.54%	278.75%
INVESTING ACTIVITIES
Capital Expenditures	-$20.40K	-$18.88K	-$182.6K
YoY Change	397.56%	-89.66%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$200.0K	-$293.3K
YoY Change	-100.0%	-31.81%
Cash From Investing Activities	$20.40K	-$218.9K	-$475.9K
YoY Change	-100.16%	-54.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$28.32M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.080K	-175.7K	25.17M
YoY Change	-112.82%	-100.7%	8578.73%
NET CHANGE
Cash From Operating Activities	-1.646M	-1.041M	-1.780M
Cash From Investing Activities	20.40K	-218.9K	-475.9K
Cash From Financing Activities	-9.080K	-175.7K	25.17M
Net Change In Cash	-1.634M	-1.435M	22.91M
YoY Change	-89.18%	-106.26%	-12829.08%
FREE CASH FLOW
Cash From Operating Activities	-$1.646M	-$1.041M	-$1.780M
Capital Expenditures	-$20.40K	-$18.88K	-$182.6K
Free Cash Flow	-$1.625M	-$1.022M	-$1.598M
YoY Change	-36.17%	-36.04%	239.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022Q3	JUPW	Impairment Of Promissory Note ImpairmentOfPromissoryNote		usd
	JUPW	Impairment Of Promissory Note ImpairmentOfPromissoryNote		usd
	JUPW	Fair Value Of Options Issued For Services FairValueOfOptionsIssuedForServices		usd
	JUPW	Amortization Clinical Research Agreement AmortizationClinicalResearchAgreement		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001760903
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	JUPW	Prepaid Clinical Research Costs PrepaidClinicalResearchCosts		usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	JUPW	Increase Decrease In Legal Fees IncreaseDecreaseInLegalFees		usd
CY2021Q3	JUPW	Impairment Of Promissory Note ImpairmentOfPromissoryNote		usd
	JUPW	Impairment Of Promissory Note ImpairmentOfPromissoryNote		usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	JUPW	Treasury Shares Cancelled TreasurySharesCancelled		usd
	JUPW	Management Common Shares Cancelled ManagementCommonSharesCancelled		usd
	JUPW	Payment To Acquired Research Agreement PaymentToAcquiredResearchAgreement		usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	JUPW	Proceeds From Acquisition ProceedsFromAcquisition		usd
	JUPW	Payment Paid For Intellectual Property PaymentPaidForIntellectualProperty		usd
	JUPW	Purchase Of Treasury Stock PurchaseOfTreasuryStock		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	JUPW	Treasury Share Cancelled TreasuryShareCancelled		usd
	JUPW	Cashless Exercise Of Options CashlessExerciseOfOptions		usd
	JUPW	Initial Rou Asset And Lease Liability InitialRouAssetAndLeaseLiability		usd
	JUPW	Fair Value Of Shares Issued For Intellectual Property FairValueOfSharesIssuedForIntellectualProperty		usd
	JUPW	Cancellation Of Shares Issued To Management CancellationOfSharesIssuedToManagement		usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39569
	dei	Entity Registrant Name EntityRegistrantName	JUPITER WELLNESS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2455880
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1061 E. Indiantown Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
	dei	Entity Address City Or Town EntityAddressCityOrTown	Jupiter
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33477
	dei	City Area Code CityAreaCode	(561)
	dei	Local Phone Number LocalPhoneNumber	244-7100
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21888888	shares
CY2021Q4	us-gaap	Assets Assets	18867465	usd
CY2022Q3	us-gaap	Cash Cash	3565488	usd
CY2021Q4	us-gaap	Cash Cash	11754558	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	397272	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	304266	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	649650	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	695319	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	880154	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	617302	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	2908300	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	2908300	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	8400864	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	16279745	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	683307	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	797311	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	309754	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	364417	usd
CY2022Q3	JUPW	Intellectual Property IntellectualProperty	375000	usd
CY2021Q4	JUPW	Intellectual Property IntellectualProperty	375000	usd
CY2022Q3	JUPW	Prepaid Clinical Research Costs PrepaidClinicalResearchCosts	1287500	usd
CY2022Q3	us-gaap	Goodwill Goodwill	941937	usd
CY2021Q4	us-gaap	Goodwill Goodwill	941937	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87195	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109055	usd
CY2022Q3	us-gaap	Assets Assets	12085557	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	572301	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1242928	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1892402	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	155050	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118102	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	295965	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	160508	usd
CY2022Q3	JUPW	Loan Payable Current LoanPayableCurrent	47981	usd
CY2021Q4	JUPW	Loan Payable Current LoanPayableCurrent	47547	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2963699	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1569085	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	564935	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	695961	usd
CY2022Q3	us-gaap	Liabilities Liabilities	3528634	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2265046	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12085557	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	JUPW	Treasury Stock Par Or Stated Value Per Share TreasuryStockParOrStatedValuePerShare	0.001
CY2021Q4	JUPW	Treasury Stock Par Or Stated Value Per Share TreasuryStockParOrStatedValuePerShare	0.001
	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	391723	shares
CY2021	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	391723	shares
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	300151	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21663888	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21663888	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24046001	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24046001	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	21664	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	24046	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50426013	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	51668019	usd
CY2022Q3	us-gaap	Convertible Debt ConvertibleDebt	477000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	285000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42067603	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35374646	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8556923	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16602419	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18867465	usd
CY2022Q3	us-gaap	Revenues Revenues	1569925	usd
CY2021Q3	us-gaap	Revenues Revenues	687928	usd
	us-gaap	Revenues Revenues	5291136	usd
	us-gaap	Revenues Revenues	1331862	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1155617	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	685769	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4255374	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1123134	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	413308	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	2159	usd
	us-gaap	Gross Profit GrossProfit	1035762	usd
	us-gaap	Gross Profit GrossProfit	208728	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2196502	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3609223	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5610585	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10336833	usd
	JUPW	Impairment Of Promissory Note ImpairmentOfPromissoryNote	1000000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2196502	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3609223	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	483	usd
CY2021Q3	us-gaap	Interest Income Other InterestIncomeOther	3139	usd
	us-gaap	Interest Income Other InterestIncomeOther	1424	usd
	us-gaap	Interest Income Other InterestIncomeOther	5288	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	549715	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	664095	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-549232	usd
	us-gaap	Operating Expenses OperatingExpenses	6610585	usd
	us-gaap	Operating Expenses OperatingExpenses	10336833	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5105	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4813	usd
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther	1199400	usd
	us-gaap	Interest Expense Other InterestExpenseOther	1124371	usd
	us-gaap	Interest Expense Other InterestExpenseOther	1696545	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1201366	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1118134	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1027162	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2332426	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4808430	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6692957	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11155267	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21530012	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19821999	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22191644	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14151337	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4393541	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28318314	usd
CY2021	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	525000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	560496	usd
CY2021	JUPW	Common Stock Issued For Services CommonStockIssuedForServices	4340983	usd
CY2021	JUPW	Adjustments To Additional Paid In Capital Contributed Capital AdjustmentsToAdditionalPaidInCapitalContributedCapital	70818	usd
CY2021	JUPW	Fair Value Of Stock Options Granted To Officers And Directors FairValueOfStockOptionsGrantedToOfficersAndDirectors	5046982	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1446530	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28100245	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16602419	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	208860	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2880045	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	277500	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	706977	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	142169	usd
	JUPW	Common Stock Issued For Services CommonStockIssuedForServices	192000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6692957	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8556923	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6692957	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11155267	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	400860	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5538821	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	72617	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	71044	usd
	JUPW	Impairment Of Promissory Note ImpairmentOfPromissoryNote	1000000	usd
	JUPW	Fair Value Of Options Issued For Services FairValueOfOptionsIssuedForServices	142169	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	996879	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1604031	usd
	JUPW	Amortization Clinical Research Agreement AmortizationClinicalResearchAgreement	212500	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-43403	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	316770	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2266	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	262852	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-159532	usd
	JUPW	Increase Decrease In Right Of Entry Assets IncreaseDecreaseInRightOfEntryAssets	-114004	usd
	JUPW	Increase Decrease In Right Of Entry Assets IncreaseDecreaseInRightOfEntryAssets	-65424	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	669200	usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	3702	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	93006	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	411108	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-670627	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	112911	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	82330	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	16438	usd
	JUPW	Increase Decrease In Legal Fees IncreaseDecreaseInLegalFees	25000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-94078	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-58029	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4750194	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5017173	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35392	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84202	usd
	JUPW	Payment To Acquired Research Agreement PaymentToAcquiredResearchAgreement	1500000	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1000000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	43000	usd
	JUPW	Proceeds From Acquisition ProceedsFromAcquisition	-293300	usd
	JUPW	Payment Paid For Intellectual Property PaymentPaidForIntellectualProperty	150000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2492392	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-527502	usd
	JUPW	Purchase Of Treasury Stock PurchaseOfTreasuryStock	2880045	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1880000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2967500	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	241272	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	187711	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	3150000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	28318314	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-946484	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28135814	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8189070	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22591139	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11754558	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4262168	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3565488	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26853307	usd
	us-gaap	Stock Issued1 StockIssued1	560496	usd
	JUPW	Feature In Connection With Convertible Notes FeatureInConnectionWithConvertibleNotes	706977	usd
	JUPW	Feature In Connection With Convertible Notes FeatureInConnectionWithConvertibleNotes	1446531	usd
	JUPW	Common Stock Issued In Connection With Promissory Notes CommonStockIssuedInConnectionWithPromissoryNotes	277500	usd
	JUPW	Treasury Share Cancelled TreasuryShareCancelled	2579894	usd
	JUPW	Cashless Exercise Of Options CashlessExerciseOfOptions	222	usd
	JUPW	Initial Rou Asset And Lease Liability InitialRouAssetAndLeaseLiability	870406	usd
	JUPW	Fair Value Of Shares Issued For Intellectual Property FairValueOfSharesIssuedForIntellectualProperty	525000	usd
	JUPW	Cancellation Of Shares Issued To Management CancellationOfSharesIssuedToManagement	57	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_840_eus-gaap--BasisOfAccounting_zo832UGJMjxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zIFZVFIq20P2">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of US Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Jupiter Wellness, Inc., a Florida corporation, Magical Beasts, LLC, a Nevada limited liability company and SRM Entertainment, Limited, a Hong Kong private limited company. All intercompany accounts and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_ziGkgsnwqAJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zqC3rgbKMOqg">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3565488	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2332426	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4808430	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6692957	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11155267	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21530012	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19821999	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22191644	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14151337	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21530012	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19821999	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22191644	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14151337	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	308690	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	300000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103025	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60529	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	649650	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	695319	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	104851	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	104851	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	880154	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	617302	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	397272	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	304266	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54663	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	72883	usd
CY2022Q3	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	309754	usd
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	364417	usd
CY2022Q3	JUPW	Intellectual Property IntellectualProperty	375000	usd
CY2021Q4	JUPW	Intellectual Property IntellectualProperty	375000	usd
CY2022Q3	JUPW	Clinical Research Agreement ClinicalResearchAgreement	1500000	usd
CY2022Q3	JUPW	Amount Of Clinical Research Agreement AmountOfClinicalResearchAgreement	3000000	usd
CY2022Q3	JUPW	Prepaid Clinical Research Costs PrepaidClinicalResearchCosts	1287500	usd
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	525000	usd
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	32856	usd
CY2021Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	525000	usd
CY2021Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	35496	usd
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	186832	shares
CY2021Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	3.00
CY2021Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	3150000	usd
CY2021Q2	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	The 2021 Notes were issued with an Original Issue Discount (“OID”) of five percent (5%), a term of six months, an annual interest rate of eight percent (8%) and convertible into shares of the Company’s common stock at a conversion price of $6.00 per share.
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	525000	shares
CY2021Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1026300	usd
CY2021Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	203532	usd
CY2021Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	62033	usd
CY2022Q3	JUPW	Original Issuance Discount OriginalIssuanceDiscount	5	pure
	us-gaap	Legal Fees LegalFees	10000	usd
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.79
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.79
CY2022Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1245279	usd
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	525000	usd
	us-gaap	Notes Issued1 NotesIssued1	2000000	usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	525000	usd
CY2021	us-gaap	Notes Issued1 NotesIssued1	3150000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3150000	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	usd
CY2020Q3	us-gaap	Loss Contingency Name Of Plaintiff LossContingencyNameOfPlaintiff	Ms. Whitley
CY2020Q3	us-gaap	Loss Contingency Name Of Defendant LossContingencyNameOfDefendant	Magical Beasts
CY2020Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1000000	usd
CY2020Q4	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	336450	usd
CY2020Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	300000	usd
CY2020Q4	JUPW	Shares Issued For Legal Settlement SharesIssuedForLegalSettlement	8500	shares
CY2020Q4	JUPW	Loss Contingency Damages Sought Value Outstanding LossContingencyDamagesSoughtValueOutstanding	691500	usd
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	669200	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21663888	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21663888	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2825617	shares
CY2021	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2825617	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24046001	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24046001	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	28318314	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	442650	shares
	JUPW	Capital Structure Description CapitalStructureDescription	the Company submitted a final compliance plan to Nasdaq consisting of the following corrective actions: (1) on July 20, 2022, the Company’s four executive officers (Messrs. John, Miller, and McKinnon and Dr. Wilson), all of whom are on the Company’s Board of Directors except for Mr. McKinnon, each cancelled 2,750 options issued to them in August 2021 pursuant to an Incentive Stock Option Forfeiture Agreement. The cancellation of the 11,000 options in total enabled the issuance of 11,000 shares to a non-executive employee that took place in 2021 to be reallocated to be accounted for as if it was originally issued under the 2020 Equity Incentive Plan. The Company’s Board of Directors passed a resolution on July 25, 2022, making the corresponding change to the Company’s books and records with regard to the 11,000 shares; and (2) on July 26, 2022, the same four executive officers, returned, and the Company cancelled, a total of 56,496 shares of common stock issued to them in 2021 outside of a shareholder approved equity compensation plan.
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.00
CY2020Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	156612	usd
CY2020Q1	us-gaap	Officers Compensation OfficersCompensation	150000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	285000	usd
	JUPW	Common Stock Issued For Services CommonStockIssuedForServices	192000	usd
	JUPW	Stock Payable StockPayable	477000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1123333	shares
CY2020Q4	JUPW	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	8.30
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	13698125	shares
CY2021Q4	JUPW	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.24
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	15158125	shares
CY2022Q3	JUPW	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.04
CY2022Q3	JUPW	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	13698125	shares
CY2022Q3	JUPW	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	3.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	300000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4383950	shares
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	211000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4975619	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4675610	shares
CY2020Q1	JUPW	Closing Cash ClosingCash	250000	usd
CY2020Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1000000	usd
CY2020Q4	JUPW	Note Payable Discount Price NotePayableDiscountPrice	950427	usd
CY2020Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	250000	shares
CY2020Q3	us-gaap	Business Combination Assets Arising From Contingencies Amount Recognized BusinessCombinationAssetsArisingFromContingenciesAmountRecognized	250000	usd
CY2020Q4	JUPW	Business Acquisiton Of Note Payable BusinessAcquisitonOfNotePayable	1000000	usd
CY2020Q4	JUPW	Business Acquisitionof Settlement Agreement BusinessAcquisitionofSettlementAgreement	336450	usd
CY2020Q4	JUPW	Business Acquisition Of Agreement Payment BusinessAcquisitionOfAgreementPayment	1000000	usd
CY2020Q4	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	300000	usd
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8500	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8500	usd
CY2020Q4	JUPW	Business Acquisiton Offset Amount BusinessAcquisitonOffsetAmount	308500	usd
CY2020Q4	JUPW	Business Acquisiton Of Note Payable BusinessAcquisitonOfNotePayable	1000000	usd
CY2021Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	334000	usd
CY2021Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	150000	usd
CY2021Q1	us-gaap	Ownshare Lending Arrangement Dividends Not Reimbursed OwnshareLendingArrangementDividendsNotReimbursed	5541	usd
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	669200	usd
CY2021Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	691500	usd
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	22300	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	180456	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	240662	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	201260	usd
CY2022Q3	JUPW	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	247882	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	224330	usd
CY2022Q3	JUPW	Lessee Operating Lease Liability Payments Due Year Eight LesseeOperatingLeaseLiabilityPaymentsDueYearEight	255319	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	229312	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	233653	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	564935	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	695961	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	46466	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	33885	usd
CY2020Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000	usd
CY2020Q3	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	5000000	usd

Files In Submission

Name	View Source	Status
0001493152-22-031766-index-headers.html	Edgar Link	pending
0001493152-22-031766-index.html	Edgar Link	pending
0001493152-22-031766.txt	Edgar Link	pending
0001493152-22-031766-xbrl.zip	Edgar Link	pending
jupw-20220930_cal.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
jupw-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
jupw-20220930_def.xml	Edgar Link	unprocessable
jupw-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
jupw-20220930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHOT
Safety Shot, Inc. Stock $shot

2022 Q4 Form 10-Q Financial Statement

#000149315222031766 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHOT Safety Shot, Inc. Stock $shot

2022 Q4 Form 10-Q Financial Statement

#000149315222031766 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHOT
Safety Shot, Inc. Stock $shot